GlassScriptPhysician profile
Amy L Albrecht
NPI 1568895993
$3,244.92
in general payments reported to CMS, 2019-2025
36 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $511 · 2023: $333 · 2024: $787 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $93.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.13 |
| Education | $93.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $473.35 | 2022-2025 | |
| Janssen Biotech, INC. | $328.98 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $290.48 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $245.98 | 2021-2025 | Enhertu, Imfinzi |
| Celgene Corporation | $158.02 | 2022-2025 | Reblozyl, Pomalyst, Recothrom |
| Glaxosmithkline, LLC. | $156.09 | 2021-2025 | Ojjaara |
| Emd Serono, INC. | $137.05 | 2021-2024 | |
| Incyte Corporation | $132.39 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $125.00 | 2021 | |
| Eisai INC. | $120.36 | 2022-2025 | |
| Genmab U.S., INC. | $114.58 | 2023 | Tivdak |
| Astellas Pharma US INC | $111.20 | 2024 | Padcev |
| Array Biopharma INC | $98.83 | 2023-2025 | Mektovi, Xalkori, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $96.29 | 2024-2025 | Opdivo, Opdualag |
| Abbvie INC. | $95.33 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $77.90 | 2021-2025 | Trodelvy |
| Springworks Therapeutics, INC. | $45.76 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $43.28 | 2022-2025 | Libtayo |
| Cti Biopharma Corp. | $32.65 | 2022-2023 | Vonjo |
| Genzyme Corporation | $31.87 | 2022-2025 | |
| Myovant Sciences INC. | $31.13 | 2022 | |
| Kite Pharma, INC. | $27.39 | 2022-2024 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $24.71 | 2023 | Imbruvica |
| Genentech USA, INC. | $24.42 | 2024 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $22.31 | 2025 | |
| Beone Medicines USA, INC. | $21.13 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $20.82 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2023 | Ninlaro |
| Tersera Therapeutics LLC | $19.30 | 2025 | Xermelo |
| Jazz Pharmaceuticals INC. | $19.09 | 2022 | |
| Beigene USA, INC. | $18.70 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $17.95 | 2025 | Orserdu |
| Adc Therapeutics America, INC. | $17.82 | 2024 | |
| Merck Sharp & Dohme LLC | $16.93 | 2024 | Keytruda |
| Amgen INC. | $16.03 | 2023 | Lumakras |
| Sobi, INC | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Albrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.